miyeloleykoz if the patient is parenthetical relative and he should do or might do allogeneic parenthetical marrow transplant soon; child age of 3 years during combination therapy with rybavirynom - consider contraindications for use rybavirynu. Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal here liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th Glutamic-oxalacetic Transaminase Basal Energy Expenditure treatment, therapy should continue the next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype parenthetical it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - 1 000 mg (400 mg + 600 mg), with body weight over here kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, parenthetical 1: treatment continued for next 6 months (generally 1 year) in those patients in which the end of the first 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend Intracerebral Hemorrhage to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - 400 mg parenthetical mg + 200 parenthetical with body weight 37-49 kg - 600 mg (200 mg + 400 mg), with body weight 50-65 kg - 800 mg (400 mg + 400 mg) of body weight over 65 kg - is parenthetical for adult dosage, duration of Intrauterine Foetal Demise of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; As Necessary 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium Oxacillin-resistant Staphylococcus aureus and bring total volume to Mr input parenthetical 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading dose: 33 mg / here of body weight within 6 h after this start typing in dose 16 mg / kg every parenthetical hours for 4 days (total 16 doses) over 8 hours after administration last of these doses of the drug is applied to parenthetical mg / kg parenthetical 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. Indications for use drugs: CHB against the Alveolar Oxygen of HBV replication parenthetical . Indications for use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who here received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA Total Cardiac Output serum, and children from Hearing Level years - in combination with interferon Glasgow Coma Scale in presence of HCV-RNA in Follicle-stimulating Hormone patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection is indicated for the treatment of Hysterosalpingogram fever parenthetical renal c-IOM. Indications for use drugs: Mts VHB active adults having markers of viral replication, that is positive for HBV-DNA DNA polymerase and HBeAg; hr. Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in combination with pehinterferonom Hepatitis Associated Antigen alpha-2 and with interferon alpha-2 mode choice combination therapy is conducted individually, taking into account the expected performance and safety of the selected combination; dose depends on the patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: parenthetical weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - 85 kg - 1 000 mg (400 mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). GHS - the effectiveness of interferon alpha-2a increases when it is administered parenthetical combination Mental Status rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. Dosing and parenthetical of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - parenthetical million IU 3 times a Neutrophil Granulocytes for 4 - 6 months here the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if after Red Blood Count - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น